Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas
- 29 August 2009
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 97 (1) , 81-88
- https://doi.org/10.1007/s11060-009-9992-3
Abstract
Perfusion estimates and microvascular leakage (MVL) were recently correlated with glioma angiogenesis and aggressiveness, but their role in predicting outcome of patients (pts) with unfavorable low-grade gliomas (ULGG) is unclear. Their prognostic value was then investigated, versus conventional factors such as age, neurological status, tumor size, and contrast enhancement (CE). Clinical and anatomical magnetic resonance imaging (MRI) criteria of a cohort of ULGG pts were prospectively evaluated. A dynamic T2*-weighted MR sequence was included to detect high-perfusion areas, using the maximal value of the relative cerebral blood volume (rCBV) estimate, and MVL. Conventional and microvascular characteristics were correlated with progression-free survival (PFS). Among the 46 pts included, the following features were present in 61%, 26%, 67%, and 26%, respectively: age ≥40 years, neurological deficits, tumor size ≥6 cm, and CE. High perfusion value was noted in 30% of cases and MVL in 52%. With median follow-up of 22 months (range 4–46 months), median PFS was 32 months [95% confidence interval (CI) 17–45 months]. On univariate analysis, CE, rCBV, and MVL were significantly correlated with PFS. On multivariate analysis, only CE and MVL were unfavorable factors, with hazard ratio of 3.0 and 7.3 and P value of 0.04 and 0.02, respectively. Different prognostic subgroups were identified, with 2-year PFS of 86%, 57%, and 19% for pts with no MVL, MVL without CE, and MVL with CE, respectively. MVL and CE seem to predict short-term outcome in ULGG pts.Keywords
This publication has 25 references indexed in Scilit:
- High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusionJournal of Magnetic Resonance Imaging, 2007
- Temozolomide for low-grade gliomasNeurology, 2007
- Comparing Perfusion Metrics Obtained from a Single Compartment Versus Pharmacokinetic Modeling Methods Using Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging with Glioma Grade2006
- Permeability versus Cerebral Blood Volume Measurement in Brain Tumor Evaluation: Comparative Clinical Value and Advice to Authors2006
- Low-Grade Gliomas: Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging—Prediction of Patient Clinical ResponseRadiology, 2006
- The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendationsBritish Journal of Cancer, 2005
- Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade GliomaJournal of Clinical Oncology, 2002
- Quantitative Measurement of Microvascular Permeability in Human Brain Tumors Achieved Using Dynamic Contrast-enhanced MR Imaging: Correlation with Histologic Grade2000
- Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.Journal of Clinical Oncology, 1997
- Perfusion imaging with NMR contrast agentsMagnetic Resonance in Medicine, 1990